Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
125514562 | 12551456 | 2 | F | 20160810 | 20160713 | 20160815 | EXP | ES-ROCHE-1792212 | ROCHE | NOTARIO FERREIRA I, FERRER GONZALEZ M; MORALES GARRIDO P, GONZALEZ UTRILLA A, GARCIA SANCHEZ A, SOTO PINO M, SUERO ROSARIO E, CARO HERNANDEZ C, ANON ONATE I, PEREZ ALBALADEJO L AND CALIZ CALIZ R. TWO-YEAR EFFICACY OF TOCILIZUMAB IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS IN CLINICAL PRACTICE. REUMATOLOGIA CLINICA 2015 OCT 09;:-. | 0.00 | Y | 0.00000 | 20160815 | OT | ES | ES |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
125514562 | 12551456 | 1 | PS | Tocilizumab | TOCILIZUMAB | 1 | Intravenous (not otherwise specified) | 125276 | 8 | MG/KG | SOLUTION FOR INFUSION |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
125514562 | 12551456 | 1 | Rheumatoid arthritis |
Outcome of event
no results found |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
125514562 | 12551456 | Gastrointestinal infection | |
125514562 | 12551456 | Infusion related reaction | |
125514562 | 12551456 | Mouth ulceration | |
125514562 | 12551456 | Neutropenia | |
125514562 | 12551456 | Respiratory tract infection | |
125514562 | 12551456 | Urinary tract infection |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
no results found |